AVXL

Anavex Life Sciences Corp. (NASDAQ:AVXL) is a clinical-stage biopharmaceutical company founded in 2004 and headquartered in New York. The company has been publicly traded since 2006 and focuses exclusively on developing treatments for central nervous system (CNS) diseases, particularly neurodegenerative and neuropsychiatric conditions. Anavex has built its pipeline around sigma receptor modulators, with its lead drug candidate <b>blarcamesine</b> (ANAVEX 2-73) currently in Phase III trials for Alzheimer's disease and having recently received marketing authorization application acceptance from the European Medicines Agency.